II. Indications
- Prevention of Motion-Induced Vomiting (Motion Sickness)
III. Mechanism
- See Neurokinin-1 Receptor Antagonist
- Tradipitant crosses the blood brain barrier to inhibit CNS Substance-P activity
- Reduces Motion-Induced Vomiting
- Blocks the neurokinin-1 receptor (NK1, a tachykinin)
- NK1 receptors are located in the ChemoreceptorTrigger Zone (Medulla Oblongata)
- Substance P normally binds NK1 to trigger Nausea and Vomiting
IV. Dosing
- Tradipitant 85-170 mg orally 60 minutes before triggering event (e.g. boating)
- Take on an empty Stomach
- Do not repeat dosing for 24 hours
VI. Adverse Effects
- Expensive (in 2026, each 85 mg capsule retails for $255; direct to consumer price $85)
- Minimal sedation (contrast with Antihistamines such as Meclizine)
- However, manufacturer recommends avoiding driving after Tradipitant due to sedation risk
VII. Safety
- Tradipitant is excreted in Breast Milk
- Observe nursing infant for Somnolence
- Unknown safety in pregnancy (not studied)
- However, no adverse effects in animal studies
VIII. Drug Interactions
- Strong CYP3A4 Inhibitors (e.g. Clarithromycin)
- Increases Tradipitant adverse effects (e.g. Somnolence)
IX. Resources
X. References
- (2026) Presc Lett 33(6): 5-6
- Feng (2026) Am Fam Physician 114(1): 96-7 [PubMed]